Table 2.

Input values in the base case analysis

	FCM	Placebo	Source
Proportion of patients according to NYHA class at baseline
NYHA class II	0.17	0.19	Anker 2009 [16]
NYHA class III	0.83	0.81	Anker 2009 [16]
Proportion of patients according to NYHA class at 24 weeks
NYHA class I	0.06	0.01	Anker 2009 [16]
NYHA class II	0.41	0.29	Anker 2009 [16]
NYHA class III	0.5	0.65	Anker 2009 [16]
NYHA class IV	0.01	0.03	Anker 2009 [16]
Death	0.02	0.03	Anker 2009 [16]
Total medication cost (IDA treatment cost)	US $645	0
FCM price (500 mg vial)	US $160	0	Suggested price
Dose	1,000 mg	0	KNF
No. of infusions	2	0	Gutzwiller 2012 [19]
Normal saline price (200 mL)	US $1.8	0	HIRA weighted price
Infusion fee	US $1.1	0	NHI fee schedule
Adjusted CHF medical cost by NYHA class excluding cost of IV iron treatment (6 months)
NYHA class I	US $510	US $510	See Table 1
NYHA class II	US $928	US $928	See Table 1
NYHA class III	US $1,623	US $1,623	See Table 1
NYHA class IV	US $3,142	US $3,142	See Table 1
Utility weight according to NYHA class (1 year)
NYHA class I	0.93	0.93	Fox 2007 [21]
NYHA class II	0.78	0.78	Fox 2007 [21]
NYHA class III	0.61	0.61	Fox 2007 [21]
NYHA class IV	0.44	0.44	Fox 2007 [21]
Utility difference from the FAIR-HF study	0.037 (scenario 2)	Gutzwiller 2012 [19]

FCM, ferric carboxymaltose; IDA, iron-deficiency anemia; KNF, Korean National Formulary; NYHA, New York Heart Association; NHI, national health insurance; No, Number; IV, intravenous.